Early Cancer Detection Using Plasma cfDNA - Multicancer Screening and Localization

Explore a comprehensive lecture on early cancer detection using plasma cell-free DNA (cfDNA) and targeted methylation assays. Delve into the challenges of single cancer screening and the potential of multi-cancer early detection tests. Learn about the biology of methylation patterns in cancer detection, clinical development programs, and large-scale studies like the Circulating Cell-free Genome Atlas (CCGA). Discover the key performance features of multi-cancer early detection tests and their potential integration into existing clinical workflows. Gain insights into the PATHFINDER study, which assesses the implementation of these tests in real-world clinical settings.

Intro
Early Diagnosis Can Dramatically Improve Cancer Survival
Significant Challenges Exist for Single Cancer Screening
Evaluation Criteria for a Multi-Cancer Early Detection Test
Tracking Down Cancer in Blood
Fragment-Level Methylation Patterns Are Tissue and Cancer-Specific
Methylation Biology Differentiates Cancer From Non-Cancer
Clinical Development Program Test development, validation, and implementation in population-scale studies
Circulating Cell-free Genome Atlas (CCGA) Study
Highly Accurate Tissue of Origin Localization
Key Performance Features of Multi-Cancer Early Detection Test Demonstrated in CCGA validation
GRAILS MCED Test Identifies More Cancers More Efficiently Than Guideline Recommended Screening Programs
A Multi-Cancer Early Detection Test Can Easily Be Integrated into Existing Clinical Workflows Evaluation for Cancer
PATHFINDER A return-of-results study to assess implementation in existing clinical workflows